Salt Lake City, Utah – January 7, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company’s groundbreaking Co-Diagnostics CoPrimer™ technology will be featured at the International Plant & Animal Genome XXVIII conference, held on January 11-15 in San Diego, CA.
The evaluation of BHQplex™ CoPrimers in flexible PCR-based genotyping will be presented by a representative of Bayer – Crop Science on Monday, January 13 in a presentation titled “CoPrimer Assays for Multiplex PCR.” According to the presentation abstract, Bayer evaluated the patented technology’s ability to enable robust and flexible multiplexing for PCR-based genotyping in several assays. This included successfully testing their performance in many different combinations and plex-levels using qPCR, end-point and digital PCR. BHQplex CoPrimers utilize the Company’s patented CoPrimer technology as branded by LGC, Biosearch, whose footprint covers over 200 countries.
The Company intends to provide additional information concerning the importance of these findings following the presentation.
More information about the PAG conference can be found on the conference website.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Co-Diagnostics Investor Relations